07 Oct 05:09
by Bo Yu,
Fei Luo,
Bowen Sun,
Wenxue Liu,
Qiqi Shi,
Shi‐Yuan Cheng,
Ceshi Chen,
Guoqiang Chen,
Yanxin Li,
Haizhong Feng
TGF-β1 potentiates KAT6A acetylation of SMAD3 at K20 and K117, which promotes SMAD3 association with oncogenic H3K23ac reader tripartite motif-containing 24 (TRIM24) and thereby increases SMAD3 transcriptional activation. Activated SMAD3 upregulates immune-related cytokines, leading to enhanced breast cancer stem-like cell properties, myeloid-derived suppressor cell (MDSC) recruitment, and triple-negative breast cancer (TNBC) metastasis. Targeting KAT6A improves the anticancer metastasis efficacy of anti-PD-L1 therapy.
Abstract
Aberrant SMAD3 activation has been implicated as a driving event in cancer metastasis, yet the underlying mechanisms are still elusive. Here, SMAD3 is identified as a nonhistone substrate of lysine acetyltransferase 6A (KAT6A). The acetylation of SMAD3 at K20 and K117 by KAT6A promotes SMAD3 association with oncogenic chromatin modifier tripartite motif-containing 24 (TRIM24) and disrupts SMAD3 interaction with tumor suppressor TRIM33. This event in turn promotes KAT6A-acetylated H3K23-mediated recruitment of TRIM24–SMAD3 complex to chromatin and thereby increases SMAD3 activation and immune response-related cytokine expression, leading to enhanced breast cancer stem-like cell stemness, myeloid-derived suppressor cell (MDSC) recruitment, and triple-negative breast cancer (TNBC) metastasis. Inhibiting KAT6A in combination with anti-PD-L1 therapy in treating TNBC xenograft-bearing animals markedly attenuates metastasis and provides a significant survival benefit. Thus, the work presents a KAT6A acetylation-dependent regulatory mechanism governing SMAD3 oncogenic function and provides insight into how targeting an epigenetic factor with immunotherapies enhances the antimetastasis efficacy.
07 Oct 05:06
by Arushi Jaiswal, Kiichi Murakami, Andrew Elia, Yukiko Shibahara, Susan J. Done, Stephen A. Wood, Nicholas J. Donato, Pamela S. Ohashi, Michael Reedijk
Triple-negative breast cancer (TNBC) is a breast cancer subtype that lacks targeted treatment options. The activation of the Notch developmental signaling pathway, which is a feature of TNBC, results in the secretion of proinflammatory cytokines and the recruitment of protumoral macrophages to the tumor microenvironment. While the Notch pathway is...
29 Jun 11:49
by Sayli Jambhulkar, Siying Liu, Pruthviraj Vala, Weiheng Xu, Dharneedar Ravichandran, Yuxiang Zhu, Kun Bi, Qiong Nian, Xiangfan Chen, and Kenan Song

ACS Nano
DOI: 10.1021/acsnano.1c03388